Elekta's latest Gamma Knife expands treatment possibilities

Elekta's latest release of its Laskell Gamma Life, for non-invasive treatment of brain disorders, offers a number of new capabilities which will give patients undergoing radiosurgery treatments more options.

"Gamma Knife surgery remains the most accurate and proven means of performing brain radiosurgery, and the single most trusted and utilized solution for treating intracranial disorders without invasive surgery," he said Jim Rose, vice president and head of marketing in North America for Elekta.

The system now offers a simplified treatment process and enhanced precision through features such as the Leksell GammaPlan 4C planning software, providing users the ability to integrate images from various image sources to achieve higher treatment precision and results.

Leksell Gamma Knife, by delivering very high doses of radiation with minimal
damage to the normal brain tissue surrounding the problem area, is used for a variety of neurological disorders, including arteriovenous malformations, vestibular schwannomas, meningiomas, pituitary tumors, trigeminal neuralgia and brain metastases.
More than 220 Gamma Knife units are in operation worldwide and over 350,000 patients have been treated, according Rose.

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.